Abstract
Pharmacogenomics is defined as the use of a person’s genetic information to individualize treatment. This is a burgeoning field which is starting to have a major impact on many areas in medicine. Notable examples are the following: The use of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) genotyping to predict response to warfarin, the use of serotonin transporter (SLC6A4) promoter length polymorphism for prediction of response to serotonin reuptake inhibitors, the use of CYP2C19 genotyping to predict response to clopidogrel, the use of HLA-B*5701 genotyping to predict hypersensitivity reactions to abacavir, and the use of HLA-B*1502 genotyping to identifying individuals of Asian ancestry who are at risk of developing Stevens–Johnson syndrome and toxic epidermal necrolysis when administered carbamazepine, phenytoin, or fosphenytoin therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61(6):409–18. doi:10.3322/caac.20134.
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–30.
Micromedex® Healthcare Series [intranet database] version 5.1. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc.
Desta Z, Ward B, Soukhova N, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310:1062–75.
Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23:9312–8.
Goetz M, Knox S, Suman V, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113–21.
Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol. 2006;24:3708–9.
Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25:5187–93.
Xu Y, Sun Y, Yao L, et al. Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008;19:1423–9.
Schroth W, Goetz M, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes amoung women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302:1429–36.
Ramon y Cajal T, Altes A, Pare L, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat. 2010;119:33–8.
Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008;99:995–9.
Newman W, Hadfield K, Latif A, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res. 2008;14:5913–8.
Nowell S, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005 Jun;91(3):49–58.
Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15, and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 2007;9:R7.
Wegman P, Vainikka L, Stal O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 2005;7:R284–90.
Okishiro M, Taguchi T, Jin K, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009;115:952–61.
Lammers L, Mathijssen R, Van Gelder T, et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patietns with metastatic breast cancer. Br J Cancer. 2010;103:765–71.
Stingl J, Parmar S, Huber-Weschselberger A, et al. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res Opin. 2010;26:2535–42.
Lim J, Chen X, Singh O, et al. Impact of CYP2D6, CYP3A5, CYP2C9, and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;71:737–50.
Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89:718–25.
Seruga B, Amir E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat. 2010;122:609–17.
Lash T, Lien E, Sorensen H, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 2009;10:825–33.
Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 1999;226:327–38.
Black J, Walker D, O’Kane D, Harmandayan M. Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction. Drug Metab Dispos. 2012;40(1):111–9. doi:10.1124/dmd.111.040832.
Hosono N, Kato M, Kiyotani K, et al. CYP2D6 genotype for functional-gene dosage analysis by allele copy number detection. Clin Chem. 2009;55:1546–54.
Kramer W, Walker D, O’Kane D, et al. CYP2D6: novel genomic structures and alleles. Pharmacogenet Genomics. 2009;19:813–22.
Ingelman-Sundberg M. Genetic polymorphisms of cytochrome p450 2D6 (CYP2D6) clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6–13.
Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442–73.
Steimer W, Zopf K, Von Amelunxen S, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CY2D6 extensive and intermediate metabolizers. Clin Chem. 2004;50:1623–33.
Gaedigk A, Simon S, Pearce R, Bradford L, Kennedy M, Leeder J. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234–42.
Raimundi S, Fischer J, Eichelbaum M, Griese E, Schwab M, Zanger U. Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6. Pharmacogenetics. 2000;10:577–81.
Bapiro T, Hasler J, Ridderstrom M, Masimirembwa C. The molecular and enzyme basis for the diminished activity of the cytochrome P450 2D6.17 variant. Biochem Pharmacol. 2002;64:1387–98.
Yu A, Kneller B, Rettie A, Haining R. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther. 2002;303:1291–300.
Raimundo S, Toscano C, Klein K, et al. A novel intronic mutation, 2988G > A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther. 2004;76:128–38.
Abduljalil K, Frank D, Gaedigk A, et al. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther. 2010;88:643–51.
Lovlie R, Daly AK, Matre GE, Molven A, Steen VM. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics. 2001;11:45–55.
Zanger U, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001;11:573–85.
American Cancer Society. Colorectal cancer facts and figures 2011–2013. Atlanta: American Cancer society; 2011.
Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert’s syndrome: two case reports. Ann Oncol. 1997;8:1049–51.
Schulz C, Boeck S, Heinemann V, Stemmler H-J. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs. 2009;20:867–79.
Xie R, Mathijssen R, Sparreboom A, Verweij J, Karlsson M. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther. 2002;72:265–75.
McLeod HL, Parodi L, Sargent D, et al. UGT1A1*28, toxicity and outcome in advanced colorectal cancer: results from trial N9741. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006;24:18S; Abstract 3520.
Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2:43–7.
Innocenti F, Undevia S, Iyer L, et al. Genetic variants in the UDP-flucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382–8.
Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921–6.
Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061–8.
Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res. 2004;10:5151–9.
Roth A, Yan P, Dietrich D, et al. Does UGT1A1*28 homozygosity predict for severe toxicity in patients treated with 5-fluorouracil (5-FU)-irinotecan (IRI)? Results of the PETACC 3-EORTC 40993-SAKK 60/00 trial comparing IRI/5-FU/folinic acid (FA) to 5-FU/FA in stage II-III colon cancer. Gastrointestinal Cancers Symposium 2008:Abstract No. 277.
Liu C, Chen P, Chiou T, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008;112:1932–40.
Kweekel D, Gelderblom H, Van der Straaten T, Antonini N, Punt C, Guchelaar H. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer. 2008;99:275–82.
Cote J, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res. 2007;13:3269–75.
Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer. 2004;91:678–82.
Seymour M, Braun M, Richman S, et al. Association of molecular markers with toxicity in a randomized trial of chemotherpya for advanced colorectal cancer (FOCUS). ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006;24:18S; (June 20 Supplement), Abstract No. 2022.
Font A, Sanchez J, Taron M, et al. Weekly regimen of inirotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs. 2003;21:435–43.
Schulz C, Heinemann V, Schalhorn A, et al. UGT1A1 gene polymorphisms: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J Gastroenterol. 2009;15:5058–66.
Innocenti F, Kroetz D, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009;27:2604–14.
Cecchin E, Innocenti F, D’Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin and irinotecan. J Clin Oncol. 2009;27:2457–65.
Akiyama Y, Fujita K, Nagashima F, et al. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol. 2008;19:2089–94.
Nakamura Y, Soda H, Oka M, et al. Randomized phase II trial of irinotecan with Paclitaxel or Gemcitabine for non-small cell lung cancer. J Thorac Oncol. 2011;6:121–7.
Takane H, Kawamoto K, Sasaki T, et al. Life-threatening toxicities in a patient iwth UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol. 2009;63:1165–9.
Saito Y, Sai K, Maekawa K, et al. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos. 2009;37:272–6.
Ikediobi O, Shin J, Nussbaum R, et al. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin Pharmacol Ther. 2009;86:28–31.
Palomaki G, Bradley L, Douglas M, Kolor K, Dotson W. Can UGT1A1 genotyping reduce morbidity and mortality in patietns with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med. 2009;11:21–34.
Gong Q-H, Cho J, Huang T, et al. Thirteen UDP-glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenomics. 2001;11:357–68.
Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA. 1998;95:8170–4.
Onoue M, Terada T, Kobayashi M, et al. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol. 2009;14:136–42.
Innocenti F, Grimsley C, Das S, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002;12:725–33.
Klein T, Chang J, Cho M, et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenomics J. 2001;1:167–70.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Black, J.L. (2014). Tamoxifen and Irinotecan Pharmacogenomics. In: Highsmith, Jr., W. (eds) Molecular Diagnostics. Molecular and Translational Medicine. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4614-8127-0_4
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8127-0_4
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4614-8126-3
Online ISBN: 978-1-4614-8127-0
eBook Packages: MedicineMedicine (R0)